Scinai Immunotherapeutics Ltd.

BVXV

US09073Q3039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-28 EDT			5-day change	1st Jan Change
3.75 ^USD	-9.42%		-1.06%	-37.02%

05-15	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
05-06	Scinai Immunotherapeutics Plans 1-for-10 Reverse Stock Split to Avoid Possible Delisting	MT

Biondvax Pharmaceuticals Ltd. Announces Resignation of Ron Babecoff from the Board of Directors Effective March 8, 2021

March 16, 2021 at 11:17 am

BiondVax Pharmaceuticals Ltd. announced resignation of Ron Babecoff from the Board of Directors effective March 8, 2021.

Latest news about Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	05-15	CI
Scinai Immunotherapeutics Plans 1-for-10 Reverse Stock Split to Avoid Possible Delisting	05-06	MT
Exchange-Traded Funds, Equity Futures Gain Slightly Pre-Bell Monday as June Rate Cut Likelihood Falls	04-08	MT
Ayana Pharma Selects Scinai Immunotherapeutics' CDMO Unit to Provide Drug Development and cGMP Manufacturing Services	04-08	CI
Scinai Immunotherapeutics Ltd. Appoints Liat Halpert as Head of Business Development and Sales	02-13	CI
Scinai Immunotherapeutics Ltd. announced that it has received $1.694259 million in funding	01-11	CI
Transcript : Scinai Immunotherapeutics Ltd. - Special Call	01-09
Scinai Immunotherapeutics Exercises Outstanding Warrants for $1.69 Million in Proceeds	12-29	MT
Scinai Immunotherapeutics Ltd. announced that it expects to receive $1.694259 million in funding	12-28	CI
Scinai Immunotherapeutics Ltd. Extends Maturity of Its Finance Facility with Scinai Immunotherapeutics from 2027 to 2031	11-29	CI
Scinai Immunotherapeutics Regains Compliance With Nasdaq's Shareholder Equity Rule	11-20	MT
Scinai Immunotherapeutics Ltd. Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting Its New CDMO Business Unit	11-06	CI
European Investment Bank Considers Extending Maturity of Scinai Immunotherapeutics Ltd. of its Financial Facility Contract	23-10-31	CI
Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
ADRs Hold Steady, Medigus Ltd. Climbs 24.5%	23-10-09	DJ
Scinai Immunotherapeutics Ltd. announced that it has received $1.329254 million in funding	23-10-02	CI
Scinai Immunotherapeutics Closes $1.3 Million Registered Direct Offering	23-09-20	MT
Scinai Immunotherapeutics Ltd. announced that it expects to receive $1.329254 million in funding	23-09-18	CI
ADRs Close Lower, Scinai Immunotherapeutics Ltd. Declines 15.5%	23-09-15	DJ
Scinai Immunotherapeutics Launches $1.33 Million Registered Direct Offering	23-09-15	MT
ADRs Advance, Brainsway Ltd. Climbs 14.0%	23-09-14	DJ
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	23-09-06	MT
BiondVax Pharmaceuticals Changes Name to Scinai Immunotherapeutics	23-09-06	MT
BiondVax Pharmaceuticals Ltd. has Changed its Name to Scinai Immunotherapeutics Ltd	23-08-24	CI
BiondVax Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI

Chart Scinai Immunotherapeutics Ltd.

Duration

Period

More charts

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Companyâs core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.75 USD

Average target price

700 USD

Spread / Average Target

+18,566.67%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SCINAI IMMUNOTHERAPEUTICS LTD.	-37.02%	1.63M
MODERNA, INC.	+54.05%	58.71B
IQVIA HOLDINGS INC.	-2.02%	41.31B
LONZA GROUP AG	+36.84%	39.2B
CELLTRION, INC.	-10.22%	27.4B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.55B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.98B
BIO-TECHNE CORPORATION	+2.89%	12.51B
UNITED THERAPEUTICS CORPORATION	+22.40%	11.94B
MEDPACE HOLDINGS, INC.	+27.49%	12.08B

Other Biotechnology & Medical Research

Scinai Immunotherapeutics Ltd.

Equities

BVXV

US09073Q3039

Biotechnology & Medical Research

Biondvax Pharmaceuticals Ltd. Announces Resignation of Ron Babecoff from the Board of Directors Effective March 8, 2021

Latest news about Scinai Immunotherapeutics Ltd.

Chart Scinai Immunotherapeutics Ltd.

Company Profile

Income Statement Evolution

Analysts' Consensus

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research